Recent Approval of Pirtobrutinib for Mantle Cell Lymphoma

H&O What is pirtobrutinib and how does it work? JC Pirtobrutinib (Jaypirca, Lilly) is a recently approved therapy for patients with relapsed or refractory mantle cell […]

Key Points From the SHINE Trial in Mantle Cell Lymphoma

H&O Could you provide some background on mantle cell lymphoma? JT Mantle cell lymphoma is an uncommon type of lymphoma. It represents approximately 6% of non-Hodgkin […]

Highlights in Mantle Cell Lymphoma From the 63rd American Society of Hematology Annual Meeting and Exposition

A Review of Selected Presentations From the 63rd ASH Meeting and Exposition December 11-14, 2021 • Atlanta, Georgia Safety and Efficacy of Acalabrutinib Plus Venetoclax and […]

Bruton Tyrosine Kinase Inhibitors for the Treatment of Mantle Cell Lymphoma: Review of Current Evidence and Future Directions

Abstract: Mantle cell lymphoma (MCL) is a heterogeneous and uncommon non-Hodgkin lymphoma that affects predominantly older patients and often is associated with an aggressive clinical […]

The Use of CAR T Cells in Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

H&O Why are new treatments needed in DLBCL and MCL? PM Existing therapies are ineffective in a subset of patients or have toxicities that make […]